weight loss drug
Ascletis’ ASC30 Enters Phase III After Mixed Phase II Data
Ascletis Pharma Inc. (HKEX: 1672) announced on August 30 that the first participant has been dosed in its global Phase III program for ASC30, an investigational once-daily oral small molecule GLP-1 receptor agonist for chronic weight management. The program consists of two pivotal trials, AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450), expected to enroll roughly 4,600 participants…
